Our commitment to Global Health

WELCOME TO HILLEMAN LABORATORIES

Bridging scientific research and industry to develop effective, affordable and sustainable

vaccines for developing world.

Developing Vaccines for Global Health

Tomorrow... is our concern and we care

Developing immunity.. Promising well being

Life is precious.. Vaccination to preserve it

Protecting life and ensuring healthy growth

Affordable and accessible vaccines forthe developing nations

OUR IDENTITYHillemanlabs @ Nanotechnology Building, Jamia Hamdard

Striving towards a healthier world since September 2009

Joint Initiative to build a vaccine R&D facility with focus on developing world

Devoted team of 30 scientists with expertise in Vaccine Development and Testing

Operating with core divisions of Upstream, Downstream, Formulations and Analytical Labs

Mission to develop thermo stable, efficacious and affordable vaccines

DR. MAURICE HILLEMANA Pioneer in Vaccine Development

"Discoveries of the cause for diseases and their prevention by vaccines... have been a hallmark for twentieth century medicine and provide a remarkable heritage for the people of the future."

Maurice R.Hilleman, PhD, DScSenior Vice President, 1957-1984

Merck Sharp & Dohme Research Laboratories

OUR APPROACH

HL carries out R&D and Clinical Assessment activities to develop vaccines for diseases that constitute almost 90% of the global burden of

diseases

HL is forging partnerships with Government, Policy Makers, Public & Private Enterprises, Research Institutes and NGOs to strengthen public health

systems and immunization programs

OUR APPROACH

Apply

Focus

Partner

OUR VISION

Philanthropy

Science

Business

OUR DREAM

Vaccine for every child

Immunize and protectHealthier force of tomorrow

Facility (GLP class)

Scientists

Infrastructure

Novel ImmunizationPlatform (HL)

OUR COMMITMENT

Reduced footprint and affordability

Thermostability

Ease of administration

OUR ADVISORS

(Director, Emory Vaccine Center)

Dr. Rafi Ahmed

Executive Director, Icddr,b Dhaka, Bangladesh

Dr. John Clemens

(Prof. & Chairman Dept. of Pediatrics & Child Health, Aga Khan UMC, Pakistan)

Dr. Zulfiqar Bhutta

(Assistant Director-General, Health Systems and Innovation)

Dr. Marie-Paule Kieny

(Board Member and Advisor for Foundations in Switzerland, Uganda, Thailand and US)

Timothy Nielander

(CEO, The Global Partnership for Education)

Alice Albright (President & Chief Executive Officer, Vedantra)

Dr. Allan Shaw

(Chairman, African Leaders Malaria Alliance and Chairman, Board AIDS Fund)

Ms. Joy Phumaphi

(President, Health Foundation of India)

Dr. K. SrinathReddy

Ms. Helen ReesProfessor of Medicine, Global Health, and PediatricsAssociate Director, Emory Vaccine CenterDirector, Emory Vaccine Policy and Development

Walter A. Orenstein, MD

Professor Helen Rees OBE MB BChir, MA (CANTAB), MRCGP, DCH, DRCOG

Mr. Michel Greco

Former President of Aventis Pasteur

OUR BOARD MEMBERS

Director, Hilleman Laboratories(Senior Vice President and Head, Global Vaccine Franchise, Merck)

Dr. James R. Baker

Director, Hilleman Laboratories(President – Vaccine Division, Merck)

Dr. Julie Gerberding

Director, Hilleman Laboratories(Director – Technology Transfer, Wellcome Trust)

Dr. A.E. Bianco

Director, Hilleman Laboratories(Senior Vice President, Manufacturing Division, Merck)

Sanat Chattopadhyay Director, Hilleman Laboratories(Chief Operating Officer, Wellcome Trust)

Simon Jeffreys

(Chairman, Hilleman Laboratories)Dr. Gerd Zeittlmeissl

Director – Hilleman Laboratories(Head of Microbial Pathogenesis (Sanger Center))

Prof. Gordon Dougan

OUR MANAGEMENT

Chief Executive Officer (MSD Wellcome Trust, Hillemanlabs)

Dr. Davinder Gill

Vice President - Finance & Company Secretary, (MSD Wellcome Trust, Hillemanlabs)

Mr. Naveen K Amar

Vice President - HR, Admin & IT, (MSD Wellcome Trust Hillemanlabs)

Mr. JaideepMukherjee Vice President -

Business Development (MSD Wellcome Trust, Hillemanlabs)

Mr. Atin Tomar

Vice President – R&D

Dr. Zimra Israel 

VACCINE RESEARCH OVERVIEW

01 02 03 04

05 06 07 08

Antigen IdentificationCandidate screeningResponsiveness

Host ProtectionImmunogenicityToxicity

SelectionImmune responseResponsiveness in large cohort

Antigen Production (Laboratory-scale)

Screening of growth mediumScreening of growth parameters

Manufacturing(Industrialscale)

Process Scale-upProcess optimization

Clinical Trail (Phase I)SafetyNon-endemic Healthy Adults> 20About 3 monthsAdverse effects

Clinical Trial (Phase II)ImmunogenicityEndemic infected/noninf.>100About 3 yearsImmune responses

Clinical Trail (Phase III)EfficacyEndemic infected/healthy>1000Up to 5 years Protection

VACCINE RESEARCH OVERVIEW

Hilleman Laboratories works extensively to bridge the gap between current vaccine candidate reliance on cold chain and low accessibility & build a new platform technology for development of thermo-stable and affordable vaccines

The current project undertaken at Hilleman Laboratories is to heat stabilize the existing vaccine candidate

Development of a thermo-stable oral thin film or granule-based rotavirus vaccine to allow for greater stability and reduce cold chain burden

Hilleman laboratories is open to collaboration for development of innovative vaccine delivery methods to develop the initial assay for the project

Hilleman Labs first project to focus on affordable access to life-saving Rotavirus vaccine to resource limited nations

R&D AT HILLEMAN LABORATORIES

Microbial and Mammalian culture Filtration and chromatographic separation

Formulation development and lyophilization/spray-dryiing

R&D AT HILLEMAN LABORATORIES

Screening and Identifying potential candidates with focus on heat stabilization

Seeding virus – cell culture – potency assay – Formulation Development

Pre-clinical evaluation – viability for commercial scale-up – Development of Delivery technology

Up-Stream Process Downstream Process Formulation & Analytics

Marketing and Distribution

Phase 3

Large Scale Manufacturing

Late Development Phase IIIClinical Trial

-> Registration

R&D AT HILLEMAN LABORATORIES

Phase 2

Early DevelopmentLead –> Phase I /II Clinical Trial

Phase 1

Basic Research Target -> Lead Candidate

R&D AT HILLEMAN LABORATORIES

Global Vaccine Needs

Feasibility

HillemanStrengths

Trans-HL management and advisory group consultation for program synergy

HL Lead Project

HL ScientificAdvisory

LeadershipProjects adopted

HL LeadershipProgram Plan

ReviewReview Strengths, Weakness

Research Proposal(from extramural, intramural, biotech, foundation)

R&D AT HILLEMAN LABORATORIES

Up-Stream Process Downstream Process Analytical

OUR CULTURE

Latest happenings

Best IndustrialPartnership in India

HOW WE PERCEIVE THE FUTURE

HILLEMAN LABORATORIES PVT. LTD.

Hilleman Laboratories Pvt. Ltd.2nd Floor, Nanotechnology Building, Jamia Hamdard, Hamdard Nagar,New Delhi – 110062 India.

Ph: +91 (11) 3099 7700Fax: +91 - (11) 3099 7711

Email: bd@hillemanlabs.orgWebsite: www.hillemanlabs.org

Office Contact: